MichaelJonPishvaianMDPhD

PubMed

• Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy.
  Ida Micaily, Edik M Blais, Randi Carhart, Sophia Lam, Steven J Cohen, Shawna J Cannaday, David Halverson, Lynn M Matrisian, Patricia DeArbeloa, Dzung Thach, Emanuel Pe...> ;JCO Precision Oncology. 2023 Sep 1
• Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-wor...
  Amol Gupta, Ana De Jesus-Acosta, Lei Zheng, Valerie Lee, Ihab Kamel, Dung Le, Michael Pishvaian, Daniel Laheru> ;Frontiers in Oncology. 2023 Jan 1
• 11 citations
  First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
  Kim, T., Burris, H., de Miguel Luken, M., Pishvaian, M., Bang, Y., Gordon, M., Awada, A., Camidge, D., Hodi, F., McArthur, G., Miller, W., Cervantes, A., Chow, L., Les...> ;Clinical Cancer Research. 2022 Aug 15
• 20 citations
  Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
  Rachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, Amy Weise, Branimir I Sikic, Osama Rahma, Daniel C Cho, Naiyer A Rizvi, Mario Sznol, Jose Lutzky, Julie E B...> ;Journal for Immunotherapy of Cancer. 2022 Aug 1
• 2 citations
  RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma.
  Fanfan Xie, Ding Ding, Cong Lin, Dea Cunningham, Michael Wright, Ammar A Javed, Nilo Azad, Valerie Lee, Ross Donehower, Ana De Jesus-Acosta, Dung T Le, Michael Pishvai...> ;JCO Precision Oncology. 2022 Jun 1
• 2 citations
  Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers.
  Michael Cerniglia, Joanne Xiu, Axel Grothey, Michael J. Pishvaian, Yasmine Baca, Jimmy J. Hwang, John L. Marshall, Ari M. Vanderwalde, Anthony F. Shields, Heinz-Josef ...> ;Molecular Cancer Therapeutics. 2021 Nov 1
• 15 citations
  Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513.
  E. Gabriela Chiorean, Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia Jalikis, Michael J. Pishvaian, Jordan Berlin, Marcus Smith Noel, Jennifer...> ;Clinical Cancer Research. 2021 Sep 27
• 12 citations
  Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies.
  Andrew Eugene Hendifar, Edik M. Blais, Brian M. Wolpin, Vivek Subbiah, Eric A. Collisson, Isha Singh, Timothy Cannon, Kenna R. Mills Shaw, Emanuel F. Petricoin, Samuel...> ;JCO Precision Oncology. 2021 Aug 25
• 14 citations
  The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria.
  Christopher W. Schultz, Grace A. McCarthy, Teena Nerwal, Avinoam Nevler, James B. DuHadaway, Matthew McCoy, Wei Jiang, Samantha Z Brown, Austin Goetz, Aditi Jain, Vale...> ;Molecular Cancer Therapeutics. 2021 Aug 19
• 10 citations
  A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies
  Neel D. Trivedi, Samantha A Armstrong, Hongkun Wang, Marion Hartley, John F. Deeken, A. Ruth He, Deepa S. Subramaniam, Heather Melville, Chris Albanese, John L. Marsha...> ;Cancer Medicine. 2021 Feb 27
• 16 citations
  Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature.
  Medhavi Gupta, Christopher Sherrow, Maghan E. Krone, Edik M. Blais, Michael J. Pishvaian, Emanuel F. Petricoin, Lynn M. Matrisian, Patricia DeArbeloa, Gary Gregory, Al...> ;Journal of the National Comprehensive Cancer Network. 2021 Jan 6
• 36 citations
  Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice
  Ivana Peran, Sivanesan Dakshanamurthy, Matthew McCoy, Anastasia Mavropoulos, Bedilu Allo, Aimy Sebastian, Nicholas R. Hum, Sara C. Sprague, Kelly A. Martin, Michael J....> ;Gastroenterology. 2021 Mar 1
• 5 citations
  A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
  Erkut Borazanci, Michael J. Pishvaian, John Nemunaitis, Colin D. Weekes, Julie Huang, Nishanthan Rajakumaraswamy> ;The Oncologist. 2020 Nov 1
• 2 citations
  The economic burden of metastatic pancreatic cancer.
  Elisabetta Malangone-Monaco, Yunes Doleh, Ashley L. Cole, Virginia Noxon, Giovanni Antico, Michael J. Pishvaian> ;Pancreatology. 2020 Sep 7
• 66 citations
  Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix
  Honglin Jiang, Robert J. Torphy, Katja Steiger, Henry Hongo, Alexa J. Ritchie, Mark Kriegsmann, David Horst, Sarah E. Umetsu, Nancy M. Joseph, Kimberly McGregor, Micha...> ;The Journal of Clinical Investigation. 2020 Sep 1
• 43 citations
  Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer
  Vincent J. Picozzi, Adnan Alseidi, Jordan Winter, Michael J. Pishvaian, Kabir Mody, John A. Glaspy, Timothy V. Larson, Marc R. Matrana, Mairead Carney, Seth Porter, El...> ;ESMO Open. 2020 Aug 1
• 87 citations
  Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
  Janice M. Mehnert, Emily K. Bergsland, Bert H. O'Neil, Armando Santoro, Jan H.M. Schellens, Roger B. Cohen, Toshihiko Doi, Patrick A. Ott, Michael J. Pishvaian, Igor P...> ;Cancer. 2020 Jul 1
• 14 citations
  A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy.
  Benjamin A. Weinberg, Hongkun Wang, Agnieszka K. Witkiewicz, John L. Marshall, Aiwu R. He, Paris Vail, Erik S. Knudsen, Michael J. Pishvaian> ;Journal of Pancreatic Cancer. 2020 Jun 22
• 12 citations
  Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis
  Yunes Doleh, Lincy S. Lal, Cori Blauer‐Petersen, Giovanni Antico, Michael J. Pishvaian> ;Cancer Medicine. 2020 May 1
• 261 citations
  Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry...
  Michael J. Pishvaian, Edik M. Blais, Jonathan R. Brody, Emily Lyons, Patricia DeArbeloa, Andrew Eugene Hendifar, Sam Mikhail, Vincent Chung, Vaibhav Sahai, Davendra So...> ;The Lancet. Oncology. 2020 Apr 1
• 3 citations
  A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.
  Cinthya Y. Lowder, Teena Dhir, Austin Goetz, Henry L. Thomsett, Joseph Bender, Talar Tatarian, Subha Madhavan, Emanuel F. Petricoin, Edik M. Blais, Harish Lavu, Jordan...> ;Surgical Oncology. 2020 Feb 8
• 7 citations
  Upfront molecular profiling of pancreatic cancer patients - An idea whose time has come.
  Manoop S. Bhutani, Irina M. Cazacu, Sinchita Roy-Chowdhuri, Anirban Maitra, Michael J. Pishvaian> ;Pancreatology. 2020 Feb 5
• 35 citations
  A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors.
  Ezra E.W. Cohen, Michael J. Pishvaian, Dale R. Shepard, Ding Wang, Jared Weiss, Melissa Lynne Johnson, Christine H. Chung, Ying Chen, Bo Huang, Craig Davis, F. Toffalo...> ;Journal for Immunotherapy of Cancer. 2019 Dec 4
• 5 citations
  Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations.
  Jun Gong, Edik M. Blais, Joseph Bender, Michelle Guan, Veronica Placencio-Hickok, Emanuel F. Petricoin, Michael J. Pishvaian, Gary Gregory, Richard Tuli, Andrew Eugene...> ;Oncotarget. 2019 Oct 22
• 42 citations
  ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications.
  Samantha A. Armstrong, Christopher W. Schultz, Ariana Azimi-Sadjadi, Jonathan R. Brody, Michael J. Pishvaian> ;Molecular Cancer Therapeutics. 2019 Nov 1
• Join now to see all

Journal Articles

• Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer  
  Pishvaian MJ, Garrido-Laguna I, Liu SV, Multani PS, Chow-Maneval E, Rolfo C., JCO Precision Oncology, 1/1/2018
• Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer  
  John Marshall, Sean Collins, Keith Unger, Aidan Burke, Marie Gurka, Michael Pishvaian, Journal of Gastrointestinal Cancer
• Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine  
  Harris M, Bhuvaneshwar K, Natarajan T, Sheahan L, Wang D, Tadesse MG, Shoulson I, Filice R, Steadman K, Pishvaian MJ, Madhavan S, Deeken J., Pharmacogenet Genomics, 1/1/2014
• Molecularly Targeted Therapy for Metastatic Colon Cancer:Proven Treatments and Promising New Agents  
  Wu C, Charabaty A, Pishvaian M, Marshall JL., Curr Colorectal Cancer Rep, 1/1/2010
• Join now to see all

Books/Book Chapters

• Hoffman and Abeloff's Hematology-Oncology Review 
  Chapter: Citation in AMA format: Isaacs C. Hoffman and Abeloffs hematology-Oncology review 
  Elsevier, Philadelphia, PAEdition 1.0,2017

Abstracts/Posters

• Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) program
  Michael J. Pishvaian, Edik Matthew Blais, Jonathan Robert Brody, Davendra Sohal, Andrew Eugene Hendifar, Vincent Chung, Sameh Mikhail, Lola Rahib, Emily Lyons, Lisa Ti..., Gastrointestinal Cancers Symposium, J Clin Oncol, 1/1/2019
• Association of DNA damage response and repair genes (DDR) mutations and microsatellite instability (MSI), PD-L1 expression, tumor mutational burden (TMB) in gastroesop...
  Michael Cerniglia, Joanne Xiu, Axel Grothey, Michael J. Pishvaian, Jimmy J. Hwang, John Marshall, Ari M. Vanderwalde, Anthony Frank Shields, Heinz-Josef Lenz, Mohamed ..., Gastrointestinal Cancers Symposium, J Clin Oncol, 1/1/2019
• A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy.
  Benjamin Adam Weinberg, Hongkun Wang, Agnieszka Katarzyna Witkiewicz, John Marshall, Erik S. Knudsen, Michael J. Pishvaian., J Clin Oncol, 1/1/2018
• Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 cl...
  Vincent J. Picozzi, Michael J. Pishvaian, Kabir Mody, Jordan Michael Winter, John A. Glaspy, Tim Larson, Marc Ryan Matrana, Khalil Saikali, Mairead Carney, Seth Porter..., J Clin Oncol, 1/1/2018
• Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).
  Stacey Stein, Michael J. Pishvaian, Michael Sangmin Lee, Kyung-Hun Lee, Sairy Hernandez, Antonia Kwan, Bo Liu, William Grossman, Koho Iizuka, Baek-Yeol Ryoo, J Clin Oncol, 1/1/2018
• Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results
  Rachel E. Sanborn, Michael J. Pishvaian, Margaret K. Callahan, Amy M. Weise, Branimir I. Sikic, Osama E. Rahma, Daniel C. Cho, Naiyer A. Rizvi, Rhonda L. Bitting, Alex..., J Clin Oncol, 1/1/2018
• A cloud-based virtual tumor board to facilitate treatment recommendations for patients with advanced cancers.
  Subha Madhavan, Edik Matthew Blais, R Joseph Bender, Vincent M. Chung, Andrew Eugene Hendifar, Sameh Mikhail, Maeve Aine Lowery, Davendra Sohal, Paula Raffin Pohlmann,..., J Clin Oncol, 1/1/2018
• Precision medicine for pancreatic cancer patients:preliminary results from the know your tumor program
  Emanuel Petricoin, R Joseph Bender, David Charles Halverson, Lola Rahib, Andrew Eugene Hendifar, Sameh Mikhail, Vincent M. Chung, Vincent J. Picozzi, Davendra Sohal, L..., J Clin Oncol, 1/1/2018
• Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).
  Mrinal M. Gounder, Michelle R. Mahoney, Brian Andrew Van Tine, Vinod Ravi, Steven Attia, Hari Anant Deshpande, Abha A. Gupta, Mohammed M. Milhem, Robert Martin Conry, ..., J Clin Oncol, 1/1/2018
• A phase II multicenter study evaluating combination immunotherapy with pembrolizumab and peginterferon alfa-2b for advanced cholangiocarcinoma.
  Aiwu Ruth He, Michael Morse, Renuka V. Iyer, Davendra Sohal, Hongkun Wang, Karen Dorsch-Vogel, Michael J. Pishvaian, Mohamed E. Salem, Brandon George Smaglo, John Mars..., J Clin Oncol, 1/1/2017
• HuR�s regulation of PARG enhances PARP inhibitor treatment of pancreatic cancer.
  Saswati N. Chand , Mahsa Zarei , Akshay R. Kamath, Matthew J. Schiewer, Carmella Romeo, Joseph A. Cozzitorto, Eric Londin, Isidore Rigoutsos, Wei Jiang, Nicole Meisner..., AACR, 1/1/2016
• Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic ...
  Wallin JJ, Pishvaian MJ, Hernandez G, Yadav M, Jhunjhunwala S, Delamarre L, He X, Powderly JD, Lieu C, Eckhardt SG, Hurwitz HI, Hochster H, Murphy JE, Leveque V, Cha E..., AACR, 1/1/2016
• Expanding the Role of Cell Cycle Inhibitors through Combination Therapy
  Pishvaian MJ, TAT, 2016 Annual Meeting, Washington, DC, 1/1/2016
• Synthetic lethality: Targeting PARP in Gastrointestinal Cancers
  Pishvaian MJ, Ohio State University, Columbus, OH, 1/1/2014
• A Phase I/II Study of ABT-888, 5-fluorouracil and oxaliplatin in patients with metastatic pancreatic cancer
  Pishvaian MJ, ASCO-GI meeting, San Francisco, CA, 1/1/2013
• A Phase II study of ABT-888 + Temozolomide in patients with heavily pretreated, metastatic colorectal cancer
  Pishvaian MJ, ASCO, Chicago, IL, 1/1/2011
• Targeted inhibition of CDK4 enhances TGF-b signaling and suppresses growth in human hepatocellular cancer cells, possibly through a rescue in b-Spectrin (ELF) and Smad...
  Pishvaian MJ, Digestive Diseases Week, Chicago, IL, 1/1/2009
• The interaction between ELF and CDK4 and cell cycle regulation in gastrointestinal cancers
  Pishvaian MJ, Digestive Diseases Week, Washington, DC, 1/1/2007
• A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC)
  Michael J. Pishvaian, Hongkun Wang, Tingting Zhuang, Aiwu Ruth He, Jimmy J. Hwang, Amy Hankin, Lisa Ley, Keisha White, Susan Joy Littman, Louis M. Weiner, John Marshal..., ASCO MEETING ABSTRACTS, J Clin Oncol, 1/30/2013
• Final results of a phase I study of lapatinib (LAP) and cetuximab (CET) in patients with CET-sensitive solid tumors
  John F. Deeken, Hongkun Wang, John Marshall, Deepa Suresh Subramaniam, Jimmy J. Hwang, Aiwu Ruth He, Corinne Ramos, Rosemarie A. Hardesty, Kenneth Steadman, Louis M. W..., ASCO MEETING ABSTRACTS, 1/17/2013
• A phase I study of the BCR-ABL tyrosine kinase inhibitor nilotinib and cetuximab in patients with solid tumors that can be treated with cetuximab.
  Brandon George Smaglo, Hongkun Wang, Kenneth Steadman, Joseph Murray, Michael Pishvaian, Aiwu Ruth He, Jimmy J. Hwang, Deepa Suresh Subramaniam, John F. Deeken, and Lo..., ASCO MEETING ABSTRACTS, 1/17/2013
• A randomized, open-label phase II study of efatutazone in combination with FOLFIRI as second-line therapy for metastatic colorectal cancer (mCRC).
  John Marshall, Dale Edward Shuster, Terri Robin Goldberg, Catherine Copigneaux, Shuquan Chen, Hamim Zahir, Dipen Dutta, Mansoor N. Saleh, Michael J. Pishvaian, Mirta S..., ASCO MEETING ABSTRACTS, 1/27/2014
• Stereotactic body radiation therapy (SBRT) combined with chemotherapy for locally advanced pancreatic adenocarcinoma.
  Marie Kate Gurka, Christine M Kim, Nadim G Haddad, John Carroll, Aline C Charabaty, Patrick G Jackson, K. William Harter, Jimmy J. Hwang, Louis M. Weiner, John Marshal..., ASCO MEETING ABSTRACTS, 1/27/2014
• Phase II trial of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma (HCC).
  Aiwu Ruth He, Anteneh Tesfaye, Daniel Smith, John Marshall, Michael J. Pishvaian, Brandon George Smaglo, Louis M. Weiner, Karen Dorsch-Vogel, and Hongkun Wang., ASCO MEETING ABSTRACTS, 1/27/2014
• Outcomes after radiation therapy for brain metastases from gastrointestinal primaries.
  Keith Robert Unger, Brian Timothy Collins, John Marshall, Michael J. Pishvaian, Ruth He, and Sean P. Collins., ASCO MEETING ABSTRACTS, 1/27/2014
• Join now to see all

Lectures

• Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionab... 
  2019 ASCO Annual Meeting - 6/1/2019
• Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC). 
  2019 ASCO Annual Meeting - 6/1/2019
• Precision Medicine in GI Cancers: Targeting the DNA Damage Repair Pathway 
  MD Anderson Cancer Center - 1/1/2018
• Precision Medicine in GI Cancers 
  School of GI Oncology - 1/1/2018
• State of the Art in GI Cancer 
  School of GI Oncology - 1/1/2018
• The Growing Reality of Precision Medicine for Cancer Patients 
  1/1/2018
• Updates in Pancreatic Cancer 
  Washington, DC - 1/1/2017
• 2017 Update in Gastrointestinal Cancer: What are the New Strategies? 
  Baltimore, MD - 1/1/2017
• The Immune Therapy Revolution in Cancer Care and Its Role in GI Cancers 
  Fairfax, VA - 1/1/2017
• GI Malignancies and Oral Therapy Options 
  Dallas, TX - 1/1/2017
• Molecular Profiling for Pancreatic Cancer 
  Dallas, TX - 1/1/2017
• Precision Medicine: The Potential for Identifying Personalized Therapies for Patients with Gastro-Esophageal Cancer 
  Washington, DC - 1/1/2016
• Colorectal Cancer: Current �Standard� Uses for Molecular Testing 
  Washington, DC - 1/1/2016
• Colorectal Cancer: How I Incorporate Molecular Profiling Into Patient Care 
  New York, NY - 1/1/2016
• Personalized Therapies for Pancreatic Cancer: Promise of Molecularly Targeted Therapies 
  Los Angeles, CA - 1/1/2016
• Pancreatic Cancer 
  Olney, MD - 1/1/2016
• Tumor Profiling for Targeted, Individualized Therapy and Improved Outcomes 
  Homestead, VA - 1/1/2016
• Molecularly Targeted Therapy for Pancreatic Cancer 
  Georgetown University, Washington, DC - 1/1/2015
• The Hope of Precision Medicine for Pancreatic Cancer 
  Washington, DC - 1/1/2015
• The Growing Reality of Personalized Therapy for Cancer Patients 
  San Diego, CA - 1/1/2015
• 2014 Update in Gastrointestinal Cancer 
  Nashville, TN - 1/1/2014
• Interpreting the Tidal Wave of Molecular Data Available from Pathology Specimens: Utilization in Treatment Decisions 
  1/1/2014
• Treatment Approaches for Pancreatic Cancer: Hope on the Horizon 
  1/1/2014
• 2013 Update in Gastrointestinal Cancer 
  Phoenix, AZ - 1/1/2013
• Biomarkers in Oncology 
  Merck, Pennsylvania - 1/1/2013
• Join now to see all

Other

• Precision Medicine for Pancreatic Cancer 
  Pancreatic Cancer Action Network Webinar
  Washington, DC - 1/1/2017
• Epidermal Growth Factor Inhibitors 
  Pishvaian M, Wang D, He R, Marshall JL, Encyclopedia of Cancer
  1/1/2009
• Molecularly Targeted Therapy for Metastatic Colon Cancer: Proven Treatments and Promising New Agents 
  Pishvaian, MJ and Wellstein, A, Cancernetwork.com
  1/1/2008